Effectiveness and safety of celecoxib combined with diacerein in the treatment of senile degenerative knee osteoarthritis: study protocol for a randomized controlled trial

doi:10.3969/j.issn.2095-4344.2017.36.002

Abstract

Abstract:

BACKGROUND: The non-steroidal anti-inflammatory drug celecoxib, used for the treatment of senile degenerative knee osteoarthritis, has a rapid onset of action and few side effects. However, it cannot prevent the occurrence and development of knee osteoarthritis. Celecoxib withdrawal is likely to induce a rebound increase in inflammation that may aggravate symptoms. Diacerein is a drug used to improve articular cartilage metabolism. It can delay the progression of senile degenerative knee osteoarthritis, but has a slow onset of action. Whether combined treatment with celecoxib and diacerein provides complimentary actions to achieve a better therapeutic effect on senile degenerative knee osteoarthritis remains unclear. Whether combined treatment with celecoxib and diacerein provides complimentary actions to achieve a better therapeutic effect on senile degenerative knee osteoarthritis remains unclear.
OBJECTIVE: To investigate the effectiveness and safety of celecoxib combined with diacerein in the treatment of senile degenerative knee osteoarthritis.
METHODS: This is a prospective, single-center, randomized controlled trial. Three hundred patients with senile degenerative knee osteoarthritis who receive treatment at the Department of Orthopedics, Second Affiliated Hospital of Nanjing Medical University, China will be randomly assigned to celecoxib (200 mg, once a day, orally), diacerein (50 mg, twice a day, orally), and celecoxib+diacerein (celecoxib 200 mg, once a day, orally and diacerein 50 mg, twice a day, orally) groups, with 100 patients in each group. Patients in each group will be treated for 12 successive weeks, and a 36-week follow-up will be performed. The primary outcome measure of this study is the 20-meter walk pain visual analogue scale score before and 1, 4, 12, 24, and 36 weeks after treatment. The secondary outcome measures of this study include osteoarthritis index and X-ray image findings of the knee before and 1, 4, 12, 24, and 36 weeks after treatment, as well as the incidence of adverse events at 1, 4, 12, 24, and 36 weeks after treatment. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanjing Medical University, China (approval No. (2017)KY-091). The study protocol will be performed in strict accordance with the Declaration of Helsinki formulated by the World Medical Association. Written informed consent of the study protocol and procedure will be obtained from each patient. Participant recruitment will begin in January 2018. Sample and data collection will begin in January 2018 and end in December 2018. Outcome measures will be analyzed in January 2020. The trial will end in February 2020. Results will be disseminated through presentations at scientific meetings and/or by publication in a peer-reviewed journal. This trial was registered with the Chinese Clinical Trial Registry (registration No. ChiCTR-IOR-17013867).
DISCUSSION: Results from this study will help to determine whether celecoxib and diacerein complement each other to produce a long-acting, safe, reliable, and rapid-onset analgesic effect in patients with senile degenerative knee osteoarthritis.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Clinical Trial, Osteoarthritis, Cartilage, Articular

CLC Number:

R318

Wang Guo-dong, Yang Ling-yun, He Bin, Wang Yun-hua, Chen Qi, Fan Lei. Effectiveness and safety of celecoxib combined with diacerein in the treatment of senile degenerative knee osteoarthritis: study protocol for a randomized controlled trial[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(36): 5747-5751.

Figures/Tables 1

References

[1] Uritani D, Fukumoto T, Myodo T, et al. The association between toe grip strength and osteoarthritis of the knee in Japanese women: a multicenter cross-sectional study. PLoS One. 2017. doi: 10.1371/journal.pone.0186454.

[2] Favero M, El-Hadi H, Belluzzi E, et al. Infrapatellar fat pad features in osteoarthritis: a histopathological and molecular study. Rheumatology (Oxford). 2017. doi: 10.1093/rheumatology/kex287.

[3] Kuttapitiya A, Assi L, Laing K, et al. Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation. Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2017-211396.

[4] Frank RM, Della Valle CJ, Plummer DR, et al. Does prior cartilage restoration impact outcomes following knee arthroplasty? Orthop Clin North Am. 2017. doi: 10.1016/j.ocl.2017.03.001.

[5] McDaniel D, Tilton E, Dominick K, et al. Histological characteristics of knee menisci in patients with osteoarthritis. Clin Anat. 2017. doi: 10.1002/ca.22920.

[6] Chang NJ, Lee KW, Chu CJ, et al. A Preclinical assessment of early continuous passive motion and treadmill therapeutic exercises for generating chondroprotective effects after anterior cruciate ligament rupture. Am J Sports Med. 2017. doi: 10.1177/0363546517704847.

[7] Ha CW, Park YB, Kyung HS, et al. Gastrointestinal safety and efficacy of long-term GCSB-5 use in patients with osteoarthritis: a 24-week, multicenter study. J Ethnopharmacol. 2016;189:310-318.

[8] Zhang XL, Yang J, Yang L, et al. Efficacy and safety of zhuanggu joint capsules in combination with celecoxib in knee osteoarthritis: a multi-center, randomized, double-blind, double-dummy, and parallel controlled trial. Chin Med J (Engl). 2016;129(8):891-897.

[9] da Costa BR, Reichenbach S, Keller N, et al. RETRACTED: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016;387:2093-2105.

[10] Lee T, Lu N, Felson DT, et al. Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. Rheumatology (Oxford). 2016;55(6):1099-1105.

[11] Rezende MU, Hernandez AJ, Oliveira CR, et al. Experimental osteoarthritis model by means of medial meniscectomy in rats and effects of diacerein administration and hyaluronic acid injection. Sao Paulo Med J. 2015;133:4-12.

[12] Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014. doi: 10.1002/14651858.CD005117.pub3.

[13] Jain A, Mishra SK, Vuddanda PR, et al. Targeting of diacerein loaded lipid nanoparticles to intra-articular cartilage using chondroitin sulfate as homing carrier for treatment of osteoarthritis in rats. Nanomedicine. 2014;10:1031-1040.

[14] McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22:363-88.

[15] 中华医学会骨科学分会.骨关节炎诊治指南(2007年版)[J].中华骨科杂志,2007,27(10):793-796.

[16] Kooistra BW, Spraque S, Bhandari M, et al. Outcomes assessment in fracture healing trials: a primer. J Orthop Trauma. 2010;24 SupplⅠ:S71-S75.

[17] Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-1840.

[18] 陈琦,何斌,王云华,等.塞来昔布联合双醋瑞因治疗膝骨关节炎的疗效观察[J].实用骨科杂志,2010,16(12):894-896.

[19] Liu GB, Zhang GP, Ren QY, et al. Classification of ankle injury on radiography and magnetic resonance imaging: study protocol for a retrospective, self-controlled, clinical trial with 3-month followup. Clin Transl Orthop. 2016;1:170-176.

[20] Chen Y, Qu S, Ma G, Meng JH, Ni XL. Femoral nerve block prevents deep venous thrombosis of the lower extremity after knee arthroplasty: a single-center randomized controlled trial. Clin Transl Orthop. 2016;1:1-5.